The Chinese medicine sector changes! A stock out of 2 consecutive boards, what information is released?

【Pharmaceutical Network Pharmaceutical Stock Market】On November 1, the traditional Chinese medicine sector changed, in terms of individual stocks, Yiming Pharmaceutical won 2 consecutive boards, Huason Pharmaceutical also opened the limit intraday, once rose more than 7%, the stock rose more than 120% in the past 12 trading days, and Darentang, Longjin Pharmaceutical, Huluwa, Longshen Rongfa and so on have followed
.
As of the close of trading on November 1, Yiming Pharmaceutical was 11.
4 yuan, down 1.
13%, with a turnover rate of 23.
29%, with a trading volume of 409,300 lots and a turnover of 499 million yuan
.
Huason Pharmaceutical closed at 27.
54 yuan on November 1, up 4.
24%, with a turnover rate of 15.
69%, a trading volume of 448,300 lots, and a turnover of 1.
223 billion yuan
.
On the news, the State Administration of Traditional Chinese Medicine recently issued the "14th Five-Year Plan for the Development of Traditional Chinese Medicine Talents", which proposed that by 2025, the total number of Chinese medicine personnel in medical and health institutions will exceed 1 million, and the number of talents related to Chinese medicine health services will grow steadily, basically meeting the demand for
Chinese medicine health services.
Among them, in terms of talent scale and talent training system, the plan is clear, by 2025, the number of practicing (assistant) physicians in the category of traditional Chinese medicine per 1,000 population will reach 0.
62, and the team of Chinese medicine professionals such as traditional Chinese medicine doctors, traditional Chinese medicine herbalists, traditional Chinese medicine nurses and traditional Chinese medicine technicians will be basically established
.
In terms of talent quality, the number of high-level talents is increasing, led by strategic scientists and Qi Huang scholars in the field of traditional Chinese medicine, and a high-level talent system with outstanding Chinese medicine clinical talents and young Qi Huang scholars as the main body has gradually formed, and the academic level and service ability of grassroots talents have been steadily improved
。 In terms of talent structure layout, by 2025, the allocation of practicing (assistant) physicians in the category of traditional Chinese medicine in public Chinese medicine hospitals above the second level shall not be less than 60% of the total number of physicians in their institutions, the proportion of practicing (assistant) physicians in the category of traditional Chinese medicine in primary medical and health institutions will continue to increase, and 100% of community health service stations and more than 80% of village clinics can provide traditional Chinese medicine services
.
According to the Ministry of Industry and Information Technology and the National Bureau of Statistics, the overall size of China's traditional Chinese medicine market has exceeded 800 billion yuan
in 2021.
The industry expects that under the background of the continuous release of national policy dividends, it is expected that the industry will maintain double-digit growth during the "14th Five-Year Plan" period, and the overall scale of the Chinese medicine market can exceed 1 trillion yuan
.
Institutions are also generally optimistic about the development of
the Chinese medicine industry.
For example, Kaiyuan Securities released a research report saying that the "14th Five-Year Plan for the Development of Chinese Medicine Talents" pointed out that Chinese medicine ushered in rare development opportunities in the world's unprecedented major changes in a century, and it was urgent to accelerate the revitalization and development of
traditional Chinese medicine.
The plan focuses on the specific tasks of the construction of various talent teams, and establishes a clearer goal of talent classification and training
.
The industry said that reviewing the relevant policies of traditional Chinese medicine, the development of the traditional Chinese medicine industry has accelerated significantly since the release of the "Opinions of the Central Committee of the Communist Party of China and the State Council on Promoting the Innovation and Development of Traditional Chinese Medicine" in October 2019, and the policy has given continuous support in traditional Chinese medicine inheritance and innovation, institutional supply, talent supply, etc.
, and the entire industry chain of traditional Chinese medicine, including research and development, planting, medical services, sales, decoction and other links, is expected to continue to benefit, so it is optimistic about the long-term development of
the traditional Chinese medicine industry 。 Xiangcai Securities also pointed out in the research report that the policy support for the Chinese medicine industry covers the entire industry chain of traditional Chinese medicine, involving upstream Chinese herbal medicine planting, traditional Chinese medicine service system, talent construction, inheritance and innovation, open development, medical insurance payment, review and approval, etc.
, and the traditional Chinese medicine industry ushered in a period
of policy dividends.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.